Physician profile
James D Allred
NPI 1669583316
$183,579.23
in general payments reported to CMS, 2019-2025
33 companies · $2,793 in 2025
The $2,793 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $36K · 2021: $24K · 2022: $39K · 2023: $4,748 · 2024: $1,523 · 2025: $2,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,125 · Honoraria: $1,500 · Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,125.00 |
| Honoraria | $1,500.00 |
| Food and Beverage | $1,437.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $54,166.55 | 2019-2022 | |
| Medtronic Vascular, INC. | $36,348.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28,190.21 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $22,312.46 | 2019-2022 | |
| Cvrx, INC. | $13,405.09 | 2019-2022 | |
| Abbott Laboratories | $12,208.66 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Medtronic, INC. | $8,299.48 | 2021-2024 | Reveal Linq, Linq II, Pulseselect |
| Medical Device Business Services, INC. | $5,209.30 | 2019-2022 | |
| Altathera Pharmaceuticals LLC | $1,500.00 | 2023 | Sotalol Hydrochloride |
| Boston Scientific Corporation | $458.65 | 2019-2022 | |
| Biotronik INC. | $329.81 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Novartis Pharmaceuticals Corporation | $224.39 | 2019-2023 | |
| Pfizer INC. | $180.41 | 2019-2025 | |
| Amgen INC. | $169.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.85 | 2019-2023 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $62.66 | 2022-2023 | Verquvo |
| Irhythm Technologies, INC. | $56.97 | 2020-2022 | |
| Daiichi Sankyo INC. | $44.62 | 2023 | Injectafer |
| Mayne Pharma Commercial LLC | $34.62 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.17 | 2019-2023 | Lifevest |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.75 | 2019 | |
| Bard Peripheral Vascular, INC. | $15.90 | 2019 | |
| Cardiovascular Systems INC. | $14.51 | 2021 | |
| Teleflex LLC | $14.09 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.44 | 2020 | |
| Amarin Pharma, INC. | $13.29 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $12.24 | 2022 | |
| Atricure, INC. | $12.21 | 2020 | |
| Chiesi USA, INC. | $12.09 | 2019 | |
| Cardiva Medical, INC. | $11.19 | 2021 | |
| Organon LLC | $6.66 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.